ASI announces Computer-Assisted PD-L1 Interpretation

ASI announces PD-L1 Interpretation, Validated, Certified & Low Cost Pathology, Histology & Cancer Research Products

ASI announces Computer-Assisted PD-L1 Interpretation

Applied Spectral Imaging (ASI) announces that its HiPath™ IHC imaging and analysis system provides computer-assisted PD-L1 interpretation.

PD-L1 is seen as the current breakthrough therapeutic target in immuno-oncology. Following recent clinical advances, PD-L1 expression has become a key factor in determining the treatment for patients with non-small cell lung cancer (NSCLC), the most common type of cancer which accounts for 13% of the total number of cancer cases in the US. The significant success of PD-1/PD-L1 blockades in lung cancer has led to the FDA approval of revolutionary immunotherapy drugs, and PD-L1 assays are becoming standard care for all patients with a suspected lung cancer.

HiPath, ASI’s flagship system for advanced IHC imaging and analysis, is a pioneer in digital pathology solutions that support PD-L1 analysis, for research use. It determines PD-L1 protein expression by calculating the percentage of viable tumour cells showing partial or complete membrane staining, and automatically provides the tumour proportion score (TPS).

To learn more about HiPath™, contact us today.


No Comments

Post A Comment